Summary. Meta-hydroxyephedrine (HED) comprises four stereoisomers consisting of two enantiomeric pairs related to ephedrine and pseudoephedrine. HED is transported into adrenergic neurons and radiolabeled HED has been employed in positron emission tomography (PET) to image adrenergic neurons in vivo. To extend structure-activity analyses of binding sites within monoamine transporters and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the HED compounds for their abilities to inhibit [ 3 H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles. We hypothesized that the HED compounds would be most potent at the norepinephrine transporter (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers. Supporting the hypotheses, all stereoisomers were most potent at the NET and the 1R,2S stereoisomer was the most potent inhibitor overall. However, the 1S,2R isomer may be preferred for PET applications because of better selectivity among the transporters and reduced neuronal recycling.
Introduction
Following their release as chemical neurotransmitters, the biogenic amines serotonin, dopamine, and norepinephrine are cleared from the synapse via their respective sodium-and chloride-dependent plasma membrane uptake transporters SERT, DAT, and NET. These transporters belong to a large family of uptake carriers with common structural features (Graham and Langer, 1992; Rudnick and Clark, 1993; Kanner, 1994; Worrall and Williams, 1994) , but the SERT, DAT, and NET differ in their substrate:ion stoichiometry (Rudnick, 1998) . The transporters also differ in their substrate selectivity, inhibitor sensitivity, and transport kinetics (Gu et al., 1994) . Once the biogenic amines have been translocated into the neuron by the plasma membrane transporters, they are packaged into synaptic vesicles by the neuronal vesicle transporter VMAT2 (Feany et al., 1992; Liu et al., 1992) . Like the plasma membrane carriers, VMAT2 is predicted to have 12 transmembrane domains (TMDs), with cytosolic amino and carboxy termini. Unlike the plasma membrane carriers, VMAT2 does not require sodium or chloride ions. Rather, the influx of neurotransmitter into the vesicle is coupled to the efflux of protons; the vesicle is supplied with protons through the action of a vesicle membrane ATP-driven proton pump (Njus, 1983; Johnson, 1987) .
In addition to translocating their respective biogenic amines, the monoamine uptake transporters will also translocate certain exogenous compounds. These compounds include phenylalkylamines such as metaraminol, 3,4-methylenedioxymethamphetamine (MDMA), and fenfluramine (Schuldiner et al., 1993; Crespi et al., 1997; Rothman et al., 1999) . The fact that the monoamine transporters can tolerate some structural diversity among substrates has been exploited in the development of drugs that can act as surrogates for the biogenic amines. Meta-hydroxyephedrine (HED), for example, is a catecholamine substrate analog that is accumulated within adrenergic neurons via the NET . HED comprises two enantiomeric pairs related to ephedrine (erythro configuration) or pseudoephedrine (threo configuration) (Fig. 1) . A radiolabeled form of one of the stereoisomers, 1R,2S [ 11 C]HED, has been employed as a positron emission tomography (PET) tracer to image adrenergic neurons in vivo. 1R,2S [ 11 C]HED was used to study the NET-mediated neuronal uptake kinetics of cardiac adrenergic terminals in an experimental model of ischemia, in disease states such as myocardial infarction and diabetic neuropathy, and in transplanted human heart (Schwaiger et al., 1991; Allman et al., 1993a,b; DeGrado et al., 1993; Di Carli et al., 1997) .
Our laboratory employs structure-activity relationship studies of monoamine transporter substrate analogs as one approach to characterizing drug binding sites within these carrier proteins. Through their ability to competitively inhibit the uptake of endogenous neurotransmitters, substrate analogs can reveal whether the monoamine carriers prefer certain structural features; these preferences are indicative of the biochemical microenvironment within the substrate binding sites of the transporters. HED is well-suited to these kinds of studies because HED comprises four stereoisomers that have identical chemical structures but differ only in the three-dimensional configuration of the amino and hydroxyl groups on the alkylamine side-chain (Fig. 1) . Any observed differences in potency among the HED isomers will indicate what parts of the ligand are important for molecular recognition by the transporters and will reflect the geometry of the substrate binding pocket within the transporters. Due to the current unavailability of the crystal structure of the transporters, this approach allows one to construct pharmacophore-based models of the substrate binding sites. These models have predictive power in drug design and must ultimately be in harmony with the three-dimensional structures of the transporters, if they are solved.
To extend our structure-activity studies of monoamine transporter ligands and to determine which of the HED isomers displays the best transporter selectivity for PET imaging applications, all four stereoisomers of HED were synthesized and tested for their abilities to inhibit monoamine neurotransmitter uptake in vitro. Among the plasma membrane uptake transporters, we hypothesized that the HED compounds would be most potent at the NET because of their structural similarity to norepinephrine. We further hypothesized that the 1R diastereomers would be more potent than the 1S diastereomers because norepinephrine itself has R stereochemistry at this position. To test for selectivity among the monoamine transporters, we examined the ability of each of the HED isomers to inhibit tritiated monoamine uptake into human platelets (SERT) or cultured cells individually expressing the cloned human DAT or NET. We also tested the HED isomers for the ability to inhibit [ 3 H]serotonin uptake into bovine chromaffin vesicles via VMAT2. By comparing the IC 50 values for monoamine uptake inhibition among the four stereoisomers, we hoped to identify structure-related differences in potency and selectivity among the monoamine transporters. In this study, we were able to detect such differences among the HED isomers. These observations should aid in modeling the transporter substrate binding sites and in the rational design of transporter-selective drugs for imaging studies and new drugs to treat diseases, such as depression, which have been associated with aberrant transporter function. 
Materials and methods

Drugs and reagents
The chemical synthesis of the four HED isomers has been reported previously by one of us (Van Dort and Tluczek, 2000) . Briefly, a mixture containing the four stereoisomers of meta-hydroxyphenylpropanolamine (MHPA) was synthesized in 20% overall yield by a seven-step synthetic route from propiophenone. The individual MHPA stereoisomers were isolated from the mixture using semipreparative chiral high pressure liquid chromatography (HPLC) as described (Van Dort, 1999) . Each stereoisomer of MHPA was converted to its respective carbamate derivative, which was then reduced to the respective HED stereoisomer with lithium aluminum hydride in refluxing tetrahydrofuran. After chromatographic purification, the HED free bases were converted to the hydrochloride salts and recrystalized. The HED isomers were characterized with respect to their physical properties by melting point (Thomas Hoover apparatus) and optical rotation (Perkin-Elmer 241 polarimeter; 589 nm) determinations. Chemical structures were confirmed by 1 H NMR spectroscopy (Bruker WM-360; 360 MHz) and by high-resolution mass spectrometry (Finnigan UG70-250-S). For uptake inhibition assays, 10 mM stock solutions of the HED isomers were individually prepared in deionized water.
[ 
Serotonin plasma membrane uptake transporter: [ 3 H]serotonin uptake into human platelets
To test drug effects on SERT-mediated [ 3 H]serotonin accumulation, human donor platelets were used. Outdated platelets were obtained from the blood bank at Pitt County Memorial Hospital, Greenville, NC. Platelets were prepared for uptake assays as previously described (Cozzi et al., 1999) . After two washes, the final pellet was suspended in 30 ml ice-cold Krebs-Ringer-HEPES (KRH) buffer containing (mM): NaCl (124.0), KCl (2.9), MgSO 4 (1.3), KH 2 PO 4 (1.2), CaCl 2 (2.4), d-glucose (5.2), HEPES (25.0), sodium ascorbate (0.1), pargyline (0.1); pH ϭ 7.4. The suspension was then stored on ice until use. For assays, a 490 µl aliquot of the platelet suspension was added to glass tubes containing either 5 µl meta-hydroxyephedrine isomer solution (various concentrations) or 5 µl KRH (for total and nonspecific determinations). The assay tubes were preincubated in a 37°C shaking water bath for 5 min. The tubes were then returned to the ice bath and chilled for 15 min. [ 3 H]Serotonin was added to each tube (5 µl of stock solution; final concentration, 15 nM), giving a total incubation volume of 500 µl. All assay tubes except nonspecific tubes were returned to the 37°C shaking water bath for 5 min to initiate neurotransmitter uptake. Uptake was terminated by chilling the test tubes in the ice bath. After adding 3 ml ice-cold 150 mM NaCl, each assay tube was vacuum filtered through glass fiber filters (Whatman GF/B) pretreated with 0.1% polyethyleneimine (PEI). Filters were washed with 2 ϫ 3 ml ice-cold 150 mM NaCl, allowed to dry briefly under vacuum, then placed in liquid scintillation vials. Scintillation cocktail (3 ml) was added and the vials were sealed, vortexed, and allowed to stand overnight. Radioactivity was measured using liquid scintillation counting (Packard Tri-Carb 1600 CA). Specific uptake was defined as uptake at 37°C minus uptake at 0°C in the absence of drugs.
Dopamine plasma membrane uptake transporter: [ 3 H]dopamine uptake into transfected cells
Human embryonic kidney cells stably expressing the human dopamine transporter (293DAT) were a gift from Dr. M. Reith (University of Illinois). Cells were maintained in a humidified atmosphere (5% CO 2 in air) in selective culture medium: Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin, 2 µg/ml puromycin). For assays, the DMEM was aspirated from 3 ϫ 100 mm dishes of confluent cells and the cells were washed three times with 37°C KRH, then harvested in 30 ml total ice-cold KRH. The cells were suspended using a polytron (setting 4, 5 sec). The ability of the test drugs to inhibit [ 3 H]dopamine uptake was measured as follows: a 490 µl aliquot of the 293DAT cell suspension was added to glass tubes, then 5 µl of meta-hydroxyephedrine isomer (various concentrations), 5 µl KRH (for total determinations), or 5 µl 10 mM cocaine hydrochloride (for nonspecific determinations; final concentration, 100 µM) was added to the appropriate tubes. The tubes were preincubated with shaking at 37°C for 10 min, then returned to the ice bath and chilled for 15 min. Five µl of [ 3 H]dopamine (final concentration, 15 nM) was added to each tube and the assay tubes were incubated with shaking at 37°C for 10 min to induce neurotransmitter uptake. Uptake was quenched by chilling the test tubes in the ice bath, then the assay tubes were diluted, filtered, worked-up, and counted as described for platelets.
Norepinephrine plasma membrane uptake transporter: [ 3 H]norepinephrine uptake into transfected cells
C6 rat glial cells stably expressing the human norepinephrine transporter (C6NET) were a gift from Dr. Susan Amara (Oregon Health Sciences University). Cells were maintained in a humidified atmosphere (5% CO 2 in air) in selective culture medium: DMEM containing 10% fetal bovine serum and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml geneticin). For assays, the DMEM was removed from 3 ϫ 100 mm dishes of confluent cells and the cells were washed with phosphate buffered saline, pH ϭ 7.1. The cells were then treated with trypsin/EDTA and split into 24-well plates. This allowed triplicate assays for total uptake, nonspecific uptake, and six drug concentrations per plate. Each well contained 1 ml of culture medium. Cells were grown overnight to confluency. The ability of the HED isomers to inhibit [ 3 H]norepinephrine uptake was measured as follows: the DMEM was aspirated from the 24-well plates, the cells were washed with 3 ϫ 2 ml 37°C KRH, and 490 µl 37°C KRH was added to each well. This was followed by the addition of 5 µl KRH (for total determinations), 5 µl 10 mM desipramine (for nonspecific determinations; final concentration, 100 µM), or 5 µl of test drug solution. The plates were preincubated at 37°C for 10 min, then 5 µl of [ 3 H]norepinephrine (final concentration, 15 nM) was added to each well to initiate uptake. Uptake was allowed to proceed for 10 min, then the incubation buffer was discarded and the cells were washed with 3 ϫ 2 ml ice-cold KRH. The cells were solubilized in 500 µl 37°C 1% sodium dodecyl sulfate, then the solubilized well contents were transferred to liquid scintillation vials containing 3 ml scintillation cocktail. Radioactivity was measured as described for platelets.
Vesicular monoamine transporter (VMAT2): [ 3 H]serotonin uptake into bovine chromaffin granules
Drug effects on VMAT2-mediated [ 3 H]serotonin accumulation were monitored in bovine chromaffin vesicles. Vesicles were prepared according to our previously reported procedure (Cozzi et al., 1999) . For uptake assays, chromaffin vesicle ghosts were diluted in assay buffer containing (mM): sucrose (300), HEPES (10), ATP (5), MgSO 4 (5), pH ϭ 7.8 to a final volume of 0.5 ml. Assays were performed in triplicate. The samples were incubated at 37°C for 10 min and then cooled on ice for 10 min. [ filters (Whatman GF/B, pretreated with 0.1% PEI) using a Brandel cell harvester (model M-48T). The filters were washed with 6 ϫ 1 ml ice-cold assay buffer minus ATP and MgSO 4 . Filters were transferred to scintillation vials and 10 ml scintillation cocktail was added. Radioactivity was measured as described for platelets.
Data analysis and statistics
All HED isomers were screened for [ 3 H]monoamine uptake inhibition at 30 µM. If at least one HED compound inhibited uptake by 50% or more at the screening concentration, the IC 50 values Ϯ standard error of the mean (S.E.M.) for all four HED isomers were determined from displacement curves from at least three experiments using six drug concentrations, each run in triplicate. Data were transformed from dpm to percent specific uptake and fitted to a four-parameter logistic curve using commercial computer software. Multiple comparisons of the HED stereoisomer IC 50 values were performed using ANOVA followed by a Student-Newman-Keuhls t-test using commercial computer software (GraphPad, San Diego, CA) with P Ͻ 0.05 considered significant.
Results
In C6NET cells, specific [
3 H]norepinephrine uptake was Ͼ90% of total uptake as defined by 100 µM desipramine. All of the HED stereoisomers passed our 30 µM screening criterion at the NET. Dose-response curves for drug inhibition of [ 3 H]norepinephrine uptake are shown in Fig. 2 with IC 50 values summarized in Table 1 . The inhibition curves had slope coefficients of unity, indicating that the HED isomers acted at a single site on the NET. The 1R,2S isomer was the most potent inhibitor of [ 3 H]norepinephrine accumulation (P Ͻ 0.05) with an IC 50 value of 0.42 Ϯ 0.04 µM. The 1S,2R and 1S,2S isomers were intermediate in potency, while the 1R,2R isomer was the least potent isomer (all P Ͻ 0.05; see Table 1 ). Thus, the rank order of potency among the HED stereoisomers at the NET is: 1R,2S Ͼ 1S,2S ϭ 1S,2R Ͼ 1R,2R. Cocaine-sensitive [ 3 H]dopamine uptake was Ն65% of total uptake in 293DAT cells. Dose-response curves for drug inhibition of [ 3 H]dopamine uptake were determined after screening at 30 µM. Like drug effects at the NET, all the DAT inhibition curves had slope coefficients that did not differ from unity. All of the HED isomers except the 1S,2R configuration exhibited IC 50 values below 30 µM. The 1R,2S and 1S,2S HED configurations were the most potent (P Ͻ 0.01) at the DAT and had similar IC 50 values (Table 1) . The 1R,2R configuration was four-fold less potent (P Ͻ 0.01) with an IC 50 of 20.8 Ϯ 2.1 µM. The 1S,2R stereoisomer was the least potent drug in the series (P Ͻ 0.01; Table 1 ). The rank order of potency among the HED isomers at the DAT is 1R,2S ϭ 1S,2S Ͼ 1R,2R Ͼ 1S,2R. The percent inhibition at 30 µM drug concentration for each isomer is as follows: 1R,2S ϭ 31.3 Ϯ 6.3%; 1S,2S ϭ 21.1 Ϯ 7.8%; 1R,2R ϭ 14.1 Ϯ 8.3%; 1S,2R ϭ no inhibition. Just as at the NET and the DAT, the HED isomer with the 1R,2S configuration appeared to be the most potent inhibitor at the SERT; the rank order of potency of the HED isomers at the SERT is 1R,2S Ͼ 1S,2S Ͼ 1R,2R Ͼ 1S,2R. The VMAT2-mediated uptake of [ 3 H]serotonin in chromaffin ghosts was Ͼ90% specific as defined by 10 µM reserpine. In this system, the 1R,2S HED isomer was again the most potent inhibitor of uptake (P Ͻ 0.05) with an IC 50 of 23.7 Ϯ 2.2 µM. The remaining drugs were substantially less potent, with IC 50 (Table 1 ). The rank order of potency at VMAT2 is therefore 1R,2S Ͼ 1S,2S Ͼ 1S,2R Ͼ 1R,2R.
Discussion
The synthesis of the individual HED stereoisomers on a milligram scale has allowed us to test these compounds for their inhibition potencies at the monoamine uptake transporters. In the present study, we compared the abilities of the four stereoisomers of HED to inhibit [ 3 H]monoamine accumulation via the plasma membrane uptake transporters and via VMAT2. We expected to see differences in potency among the HED isomers at the plasma membrane transporters due to the different configurations of the side-chain amine group. Among monoamine ligands, the (protonated) amine nitrogen has been proposed to form an ionic bond with a conserved aspartate residue in TMD1 of the plasma membrane transporters (Kitayama et al., 1992; Barker et al., 1999) . We thought that this interaction would be sensitive to the spatial placement of the amine. Our expectation was borne out at the SERT and DAT: the stereochemistry of the side-chain amine group dominates the binding interaction in these transporters. The 2S diastereomers were more potent than the 2R diastereomers, regardless of the configuration at the 1-position (Table 1) . In addition to a potentially more productive electronic alignment with the conserved aspartic acid residue, the 2S isomers may also benefit from a favorable steric environment for binding (e.g. complementary pocket), or through some combination of these. The stereochemistry at the 1-position played a lesser, but still significant, role: the 1R diastereomers were more potent than the 1S diastereomers, once the effect of the 2-position is taken into account. Thus, despite the absence of stereogenic centers in serotonin and dopamine, the substrate binding domains within the SERT and DAT favor certain topological or electronic configurations in ligand side chains. The fact that the HED isomers, like dopamine, are phenylalkylamines may partly explain the increased potency among these drugs at the DAT compared to the SERT; the SERT would be expected to prefer indolealkylamine substrates. Nevertheless, there exist phenylalkylamines that are quite potent competitive inhibitors of SERT-mediated [ 3 H]serotonin uptake (Huang et al., 1992; Monte et al., 1993; Crespi et al., 1997) .
We hypothesized that the HED compounds would be most potent at the NET because of their structural similarity to norepinephrine i.e. the HED isomers and norepinephrine all contain a hydroxyl moiety on the side-chain. Supporting our hypothesis, each of the HED compounds exhibited higher affinities for the NET than for any of the other transporters (Table 1 ). In particular, the HED compounds were more effective inhibitors at the NET than at the highly homologous DAT and SERT proteins. A reasonable explanation for this observation stems from the fact that while the NET will effectively transport both norepinephrine and dopamine, the DAT and SERT are not efficient transporters of norepinephrine (Pacholczyk et al., 1991; Giros et al., 1992) . We propose that in norepinephrine, the side-chain hydroxyl is an essential feature in the molecular exclusion of norepinephrine by the DAT and the SERT, either through an unfavorable electrostatic interaction involving the side-chain hydroxyl group or through steric occlusion within the substrate binding site. The HED compounds, like norepinephrine, incorporate a hydroxyl group at the side-chain 1-position and would therefore be expected to encounter the same interference at the DAT and SERT as norepinephrine, leading to the observed higher affinity at the NET compared to the DAT and the SERT. The presence of the side-chain hydroxyl also imparts chirality to the carbon at the 1-position, and, in norepinephrine, the stereochemistry is R. We hypothesized that both of the HED diastereomers with the 1R configuration would more closely mimic norepinephrine and would therefore be the most potent inhibitors of [ 3 H]norepinephrine uptake. As our data shows, the most potent inhibitor of [ 3 H]norepinephrine uptake does have 1R stereochemistry. This is the HED isomer with the 1R,2S configuration. This drug was the most potent inhibitor of monoamine uptake across all the plasma membrane transporters, and has an IC 50 of only 0.42 µM at the NET (Table 1) . Continuing the trend observed at the SERT and DAT, the 1R,2S diastereomer was also more potent (about 16-fold) than the 1R,2R configuration. However, the difference in potency between the 2-position isomers is not manifested in the 1S HED stereopair: when the stereochemistry is 1S, the configuration at the side-chain 2-position has no effect on affinity at the NET (1S,2S ϭ 1S,2R; Table 1 ). Furthermore, the 1S diastereomers were less potent than the 1R,2S isomer but not the 1R,2R isomer. As submitted above, we had expected both of the 1R compounds to be more "norepinephrine-like" and therefore more effective than both of the 1S compounds, but this was not the case. These results suggest that the amino acid residues involved in ligand side-chain recognition within the NET substrate site may interact with one another and with the ligand in a complex way. Losses in affinity due to a suboptimal configuration at one side-chain carbon may be offset by gains in affinity at the other carbon; modifications to one site on the ligand can induce changes in affinity that are not simply additive with respect to the other site.
The bovine chromaffin vesicle is a well-accepted model for VMAT2-mediated uptake into synaptic vesicles. The human and bovine VMAT2 exhibit similar pharmacological profiles for substrates and inhibitors (Schuldiner et al., 1995) , making bovine vesicles useful for studying drugs that act at VMAT2. In the present study, only the 1R,2S HED isomer displayed halfmaximal inhibition at less than 30 µM at VMAT2. As was seen at the DAT and SERT, the 2S diastereomers were more effective than the 2R diastereomers, regardless of the configuration at the 1-position (Table 1) , again suggesting that the substrate binding site is asymmetric even though the endogenous ligands are not themselves chiral. The low affinity of the HED compounds at VMAT2 is remarkable because VMAT2 is relatively indiscriminate with regard to arylalkylamine binding. Many structurally dissimilar molecules including tryptamine, histamine, serotonin, dopamine, 5-methoxy-6-methyl-2-aminoindan, 3-methoxy-4-methylamphetamine, methamphetamine, and MDMA inhibit VMAT2-mediated neurotransmitter uptake in the nanomolar to low micromolar range Finn and Edwards, 1997; Cozzi et al., 1999) .
Our findings have important implications for the design of PET radiotracers for imaging sympathetic neurons. In clinical studies, 1R,2S [ 11 C]HED demonstrates a high initial myocardial uptake and a prolonged tissue clearance consistent with a slow turnover of the radiotracer (DeGrado et al., 1993) . The neuronal accumulation of a neurotransmitter or a drug analog is the net result of uptake, vesicular storage, and neuronal clearance processes such as metabolism. 1R,2S HED and its stereoisomers incorporate a methyl group α to the amino moiety ( Fig. 1 ) which make these derivatives resistant to metabolism by monoamine oxidase (MAO) present in sympathetic nerve terminals. Additionally, due to its lower VMAT2 affinity as compared to norepinephrine, 1R,2S [
11 C]HED is more likely than norepinephrine to diffuse out of the neuron into the synapse where it can once again undergo neuronal uptake by the NET. Thus, the extended tissue half-life of 1R,2S [ 11 C]HED may be explained by its tendency to undergo indefinite neuronal recycling due to a combination of decreased metabolism, poor vesicular retention, and uptake via the NET. Given that all of the HED compounds are poor substrates for MAO and have low affinity for VMAT2, their relative affinity for the NET then becomes the dominant factor in neuronal recycling and clearance. Due to its lower NET affinity and better overall selectivity among all the monoamine uptake transporters (Table 1) , the 1S,2R stereoisomer may be a better choice than the 1R,2S isomer for compartmental modeling by PET imaging. In summary, there were modest but clear differences in potency among the test drugs based upon the stereochemical configuration of the HED sidechain. The 1R,2S HED stereoisomer was the preferred configuration at all the plasma membrane transporters and at VMAT2. Although each of the four monoamine carriers examined in this study is a unique protein, they all favor 1R,2S stereochemistry in substrate-like ligands, suggesting that the substrate binding pockets within these transporters are at least grossly similar. Our data also indicate that the 1S,2R HED isomer may be a better candidate for PET imaging than the 1R,2S stereoisomer due to its lower NET and VMAT2 affinities and better overall selectivity for the NET compared to the DAT, SERT, and VMAT2.
